1. Introduction {#sec1}
===============

The Na^+^-[d]{.smallcaps}-glucose cotransporter 1 (SGLT1) is encoded by the *Slc5a1* gene predominantly expressed in the small intestine [@bib1], [@bib2]. In addition, SGLT1 expression was also shown in various other tissues such as kidney, lung, liver, heart, brain, uterus, and pancreas [@bib1], [@bib2], [@bib3], [@bib4], [@bib5], [@bib6]; with the exception of the small intestine, kidney, and uterus, tissue-specific function is widely unknown.

The classical role of small intestinal SGLT1 is secondary, active Na^+^-[d]{.smallcaps}-glucose cotransport across the apical membrane, which is rate-limiting for intestinal glucose absorption from food [@bib2], [@bib7], [@bib8]. Additionally, along with the glucose transport, incretins such as glucagon-like peptide 1 (GLP-1) are secreted [@bib9], [@bib10], [@bib11]. Incretins, especially GLP-1, act on pancreatic islets contributing to the regulation of insulin secretion from β-cells [@bib9], [@bib10], [@bib11]. Functional impairments are seen when SGLT1 is abrogated. Humans carrying mutations in SGLT1 display a diminished capacity for small intestinal glucose transport [@bib12]. Further, aberrant glucose-stimulated insulin or GLP-1 responses were reported for SGLT1 inhibition or knockout (SGLT1^−/−^) mice [@bib7], [@bib8], [@bib13], [@bib14], [@bib15]. Consequently, SGLT1 plays a crucial role in the regulation of blood glucose homeostasis.

Maintaining blood glucose homeostasis is of high importance for type 2 diabetes (T2D) patients. T2D is a widespread disease with severe long-term associated complications that is characterized by hyperglycemia, decreased insulin sensitivity of target tissues, and decreased insulin secretion of pancreatic β-cells. Pharmacological agents regulating blood glucose levels under diabetic conditions represent a promising treatment strategy. After successful establishment of Na^+^-[d]{.smallcaps}-glucose cotransporter 2 (SGLT2) inhibitors blocking renal glucose reabsorption, inhibitors of SGLT1 that block small intestinal glucose absorption have been proposed recently as an additional therapeutic intervention strategy [@bib14], [@bib15], [@bib16]. Preclinical studies and first clinical trials show that the application of SGLT1 inhibitors, alone or in combination with SGLT2 inhibition, improve postprandial hyperglycemia in diabetic patients [@bib15], [@bib16], [@bib17], [@bib18]. However, effects of long-term treatment have not been evaluated in detail. In addition, there is considerable uncertainty concerning potential side effects. Diarrhea, abdominal pain, and flatulence have been reported [@bib16], but there is some disagreement whether these effects may be moderate if complete blockage of SGLT1 is avoided [@bib19]. Studies in humans or mice kept on a standard diet exhibiting defect mutations in SGLT1 similarly demonstrated intestinal malabsorption of glucose and galactose associated with diarrhea and metabolic acidosis [@bib7], [@bib8], [@bib12], [@bib20]. Further, endometrial side effects were shown for SGLT1 knockout mice [@bib5]. Knowledge about adverse events in other SGLT1 expressing tissues is largely missing.

In view of the recently reported SGLT1 expression in pancreatic islet cells [@bib3], [@bib6] together with the atypical insulin responses reported for SGLT1^−/−^ mice [@bib7], [@bib8] and the current interest in pharmacological SGLT1 inhibition, the aim of our work was to investigate possible side effects on pancreatic islets when SGLT1 is lost. This may also contribute to a better understanding of a pancreas-specific SGLT1 function.

2. Methods {#sec2}
==========

2.1. Animal handling {#sec2.1}
--------------------

Animal research was performed according to German law and institutional guidelines approved by the Ethics Committee of the District of Unterfranken, Würzburg, Germany (approval number: 55.2-2531.01-45/14). Mice were housed with free access to food and water *ad libitum* at 12 h light and dark cycles. Wild type mice and SGLT1^−/−^ mice on C57BL6/J background were fed with two different but equicaloric diets both containing about 13 MJ kg^−1^ as described [@bib7]. Standard chow (SC) was obtained from Altromin (Lage, Germany; \#1320) containing 36.4% starch, 19% protein, 4.9% fiber, 4.7% mono- and disaccharides, 3.3% fat, minerals and vitamins. The glucose-deficient, fat-enriched diet (GDFE) in which energy content was supplemented by increased fat and protein was composed of 33.8% protein, 30.7% fiber, 20.5% fat, minerals and vitamins (Altromin, Lage, Germany \#C-1073). Three animal groups were compared: wild type mice fed with SC (WT-SC), wild type or SGLT1^−/−^ mice fed with GDFE (WT-GDFE or SGLT1^−/−^-GDFE mice). Diets were applied directly after weaning, and analyses were performed in 12 - 14 week old animals.

2.2. Oral glucose tolerance test (OGTT) and *in vitro* glucose measurement {#sec2.2}
--------------------------------------------------------------------------

Animals were deprived of food 12 h prior to administration of [d]{.smallcaps}-glucose (6 mg/g body weight). PBS served as control. Blood samples were taken 5 or 60 min after bolus from the left heart of sacrificed animals followed by dilution in citrate buffer (pH 4.5) substituted with 100 μmol/L dipeptidyl peptidase (DPP)-IV inhibitor (Merck Millipore, Darmstadt, Germany). Plasma insulin or GLP-1 values were analyzed using the insulin ultrasensitive mouse ELISA (80-INSMSU-E01, Alpco, Salem, USA), the total GLP-1 ELISA (EZGLP1T-36K, Merck Millipore, Darmstadt, Germany) or the Glucagon ELISA (10-1281-01, Mercodia, Uppsala, Sweden). For blood glucose determination the Glucose Colorimetric Assay Kit (10009582, Cayman Chemicals, Ann Arbor, U.S.A.) was used following manufacturer\'s instructions.

2.3. Islet isolation and glucose-stimulated insulin secretion (GSIS) {#sec2.3}
--------------------------------------------------------------------

Pancreatic islets were isolated as described with modifications [@bib21], [@bib22]. Briefly, islets were obtained by perfusion of pancreata with Collagenase P (1.2 mg/ml, Roche, Basel, Switzerland) dissolved in 2 ml RPMI 1640 medium through the common bile duct followed by organ isolation and enzymatic dissociation at 37 °C. After washing, islets and the exocrine pancreatic tissue were separated by Ficoll Paque (GE Healthcare, Chicago, USA) gradient centrifugation followed by hand-picking of islets. Prior to glucose stimulation, islets were cultured at 37 °C for 90 min in RPMI 1640, 10% FCS, 1x GlutaMax, 20 mM HEPES sodium salt solution and 1x Penicillin-Streptomycin followed by 30 min incubation in 3.3 mM [d]{.smallcaps}-glucose dissolved in Krebs buffer working solution (137 mM NaCl, 4.7 mM KCl, 1.2 mM KH~2~PO~4~, 1.2 mM MgSO~4~, 2.5 mM CaCl~2~, 25 mM NaHCO~3~). Afterwards, islets were stimulated in 3.3 mM or 16.7 mM [d]{.smallcaps}-glucose solution. After 1 h, supernatants were removed and analyzed for insulin concentration using the ultrasensitive mouse insulin ELISA (Alpco, Salem, USA). DNA content was quantified with the Quant-it dsDNA PicoGreen Kit (Thermo Fisher, Darmstadt, Germany). Stimulation index was calculated by dividing high glucose insulin/DNA ratio by low glucose insulin/DNA ratio.

2.4. Hematoxylin-eosin (H&E) and immunohistological (IHC) analyses {#sec2.4}
------------------------------------------------------------------

H&E staining\'s were performed according to a standard protocol. Prior to IHC stainings, sections were rehydrated. Heat-induced epitope retrieval was achieved by 20 min boiling in citrate buffer (pH 6). After permeabilization by Triton X-treatment (0.2%), unspecific binding sites were blocked by incubation in 5% (v/v) donkey serum, 0.5% BSA (w/v) and 0.2% Saponin (w/v) or in 5% BSA only. Primary antibodies were incubated at 4 °C overnight. Next day and after several rounds of washing, sections were incubated with secondary antibodies at room-temperature for 1 h before additional washing steps and mounting in Fluoromount-G containing DAPI. Antibodies are listed in [Supplementary Table 1](#appsec1){ref-type="sec"}. Analysis was performed using inverse fluorescence (BZ-7000, Keyence, Tokyo, Japan) or confocal microscopy (TCS SP8, Leica Microsystems, Wetzlar, Germany). Quantification of islet size and determination of cell numbers was performed on H&E-stained sections using Image J and the ImageJ Cell Counter plugin (ImageJ, National Institutes of Health, Bethesda, USA). Triglyceride staining was performed using Oil Red O (Sigma Aldrich, Munich, Germany) according to manufacturer\'s instructions.

2.5. Apoptosis assay {#sec2.5}
--------------------

Islets were isolated as described and dissociated into single cell suspensions using 0.05% trypsin-EDTA (v/v) for 5 min at 37 °C. Single cell suspensions were analyzed for apoptotic cell numbers using the fluorochrome-labeled Annexin V apoptosis kit (BioLegend, San Diego, USA) according to manufacturer\'s instructions and the BD Accuri™ C6 Cytometer (BD Biosciences, Heidelberg, Germany).

2.6. Quantitative (q)RT-PCR {#sec2.6}
---------------------------

RNA was isolated using the RNeasy Micro or Mini Kit and cDNA was synthesized with the iScript^™^ cDNA Synthesis Kit (Biorad, Munich, Germany). qRT-PCR was performed on the CFX96 Touch^™^ Real-Time PCR Detection System (Biorad) using SsoFast^™^ EvaGreen^®^ Supermix (Biorad). Gene expression was calculated by the 2^−ΔΔCt^ method with *RPL15* as reference gene. All reactions were performed in duplicates at 60 °C annealing temperature. Primers were applied at 4 pmol/μl. Primer sequences are shown in [Supplementary Table 2](#appsec1){ref-type="sec"}.

2.7. Statistical analysis {#sec2.7}
-------------------------

If not otherwise described, data are shown as mean ± standard deviation (SD). Comparing mean values of three or more conditions, significance of differences was analyzed using one-way ANOVA with posthoc Tukey comparison. Significance between two mean values was determined by Student\'s *t*-test. Statistical analysis was performed with Graph Pad Prism 6.07 (GraphPad Software Inc., La Jolla, USA). P \< 0.05 was considered statistically significant.

3. Results {#sec3}
==========

3.1. Glucose-deficient, fat-enriched diet impacts small intestinal but not pancreatic SGLT1 mRNA expression {#sec3.1}
-----------------------------------------------------------------------------------------------------------

SGLT1 is predominantly expressed in the small intestine; however, protein and/or mRNA of SGLT1 has also been detected in various additional organs including the pancreas [@bib1], [@bib2], [@bib3], [@bib5], [@bib6], [@bib23], [@bib24]. Consistent with earlier findings [@bib3], [@bib6], [@bib23], we observed SGLT1 mRNA expression in small intestine (SI), pancreatic islets (PIs), and pancreatic exocrine tissue (EXT) of WT-SC mice ([Figure 1](#fig1){ref-type="fig"}). Compared to SI, SGLT1 mRNA expression in PIs or EXT was only 0.23% or 0.28%, respectively ([Figure 1](#fig1){ref-type="fig"}A). In addition to tissue-specific transcription [@bib1], [@bib2], [@bib23], nutrient-dependent regulation was shown for small intestinal SGLT1 mRNA expression [@bib1], [@bib25], [@bib26], [@bib27]. We observed that SGLT1 mRNA expression in SI of WT-GDFE mice was downregulated by 84.1% compared to WT-SC controls ([Figure 1](#fig1){ref-type="fig"}B). In line with the decrease in mRNA expression, also blood glucose levels were significantly reduced in WT-GDFE mice 5 min post glucose administration compared to WT-SC controls ([Supplementary Fig. 1](#appsec1){ref-type="sec"}). In contrast to the intestine, SGLT1 mRNA expression levels in PIs and EXT of WT mice on SC or GDFE were similar ([Figure 1](#fig1){ref-type="fig"}C and D). Of note, there was a huge variation for SGLT1 mRNA expression observed in WT-GDFE PIs and EXT; however, the reason remains elusive ([Figure 1](#fig1){ref-type="fig"}C and D). As expected no significant expression of SGLT1 mRNA could be detected in SGLT1^−/−^-GDFE mice ([Figure 1](#fig1){ref-type="fig"}B--D). Also, no increase in blood glucose was observed in SGLT1^−/−^-GDFE mice 5 min post glucose administration while all mice displayed comparable blood glucose levels after a 12 h fasting period ([Supplementary Fig. 1A--B](#appsec1){ref-type="sec"}).Figure 1**SGLT1 mRNA expression in small intestine (SI), pancreatic islets (PI) and pancreatic exocrine tissue (EXT) isolated from WT-SC, WT-GDFE or SGLT1**^**−/−**^**-GDFE mice.** SGLT1 mRNA levels were determined by quantitative RT-PCR using the 2^−ΔΔCt^ method with murine *(m)RPL15* as reference gene. **(A)** Comparison of SGLT1 mRNA expression in SI, PIs, and EXT of WT-SC mice. Data are presented relative to SGLT1 mRNA expression in SI and are shown as means ± SD with indication of individual measurements. For calculation, each biological replicate of SI-specific SGLT1 mRNA expression was set to 1. **(B**--**D)** Comparison of SGLT1 mRNA expression in SI (B), PI (C), or EXT (D) between WT-SC, WT-GDFE, and SGLT1^−/−^-GDFE mice. Data are presented relative to SGLT1 mRNA expression in WT-SC mice and are shown as means ± SD with indication of individual measurements. For calculation, expression in WT-SC mice was set to 1 for each biological replicate. Experiments were performed with female mice (*n* = *6*)*.* \*\*\**P* \< 0.001, ns = not significant one-way ANOVA with posthoc Tukey test.Figure 1

3.2. Pancreatic islets of SGLT1^−/−^-GDFE mice show increased sizes associated with elevated cell numbers, decreased cellular proliferation, and a reduction in apoptotic cells {#sec3.2}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

In the current study, we aimed to investigate if SGLT1 knockout impacts PIs. To this aim, we first investigated morphological aspects of PIs analyzing islet areas in WT-SC, WT-GDFE, and SGLT1^−/−^-GDFE mice ([Figure 2](#fig2){ref-type="fig"} and B; [Supplementary Fig. 2](#appsec1){ref-type="sec"}). Whereas no significant difference was detected between WT-SC and WT-GDFE mice, a 48% larger compiled islet area was observed in SGLT1^−/−^-GDFE mice compared to WT-GDFE mice. To determine whether the increased, compiled PI area was due to an increase of islet size, we compared islet sizes between WT-SC, WT-GDFE, and SGLT1^−/−^-GDFE mice ([Figure 2](#fig2){ref-type="fig"}C). Islet sizes are known to vary from small to large and islet size distribution patterns are influenced by physiological or pathological conditions [@bib28]. Dividing the pancreatic islets into small islets comprising areas \<12 × 10^3^ μm^2^ and large islets with areas \>12 × 10^3^ μm^2^, we observed 19% large islets in WT-SC mice, 29% in WT-GDFE mice and 39% in SGLT1^−/−^-GDFE mice ([Figure 2](#fig2){ref-type="fig"}C). To investigate whether the increased islet sizes observed for WT-GDFE and SGLT1^−/−^-GDFE mice ([Figure 2](#fig2){ref-type="fig"}A) correlated with a change in cellular density, we determined the amount of cell nuclei in pancreatic islets per area without differentiating between small and large islets. Our data showed no significant differences between all three groups ([Figure 2](#fig2){ref-type="fig"}D). In contrast to cellular density but consistent with the larger compiled islet area ([Figure 2](#fig2){ref-type="fig"}A), we observed a 60% higher number of cells per islet in SGLT1^−/−^-GDFE compared to WT-GDFE mice whereas cell numbers per islet for WT-SC and WT-GDFE mice were similar ([Figure 2](#fig2){ref-type="fig"}E). To further evaluate whether the higher number of islet cells in SGLT1^−/−^-GDFE mice was due to changes in proliferation and/or apoptosis, we first determined the fraction of cells per islet expressing the proliferation marker KI67 [@bib29] without differentiating between islet sizes ([Figure 2](#fig2){ref-type="fig"}F; [Supplementary Fig. 3](#appsec1){ref-type="sec"}). In WT-SC mice, about 1.64 ± 0.42 KI67^+^ cells per islet were observed. Whereas no diet-dependent effect was detected, the number of KI67^+^ cells in SGLT1^−/−^-GDFE mice (0.47 ± 0.15) was significantly reduced compared to WT-GDFE mice (1.14 ± 0.29). We further determined the number of apoptotic cells by flow cytometry analysis. [Figure 2](#fig2){ref-type="fig"}G shows fold changes of apoptotic cell numbers of WT-GDFE and SGLT1^−/−^-GDFE mice relative to WT-SC mice. While no difference was observed between WT-SC and WT-GDFE mice, PIs of SGLT1^−/−^-GDFE mice showed 2.3-fold less apoptotic cell numbers compared to WT-GDFE mice ([Figure 2](#fig2){ref-type="fig"}G; [Supplementary Fig. 4](#appsec1){ref-type="sec"}).Figure 2**Comparison of compiled islet area, proportion of large islets, cell numbers per pancreatic islets (PIs), PI-specific proliferation, and apoptosis in WT-SC, WT-GDFE, and SGLT1**^**−/−**^**-GDFE mice.** Data are shown as means $\pm$ SD. **(A)** Compiled areas of PIs. Per animal, 4--6 H&E-stained sections from different stacks (see [Supplementary Fig. 2](#appsec1){ref-type="sec"}) were used for determination of compiled islet areas. Shown are the average compiled areas for each group. Measurements from individual animals and mean values ± SD are shown (*n* = *6*)*.***(B)** Representative microscopic pictures of H&E-stained pancreas sections of WT-SC, WT-GDFE, and SGLT1^−/−^-GDFE mice. Scale bar = 300 μm. **(C)** Proportions of pancreatic islets with areas \> 12 × 10^3^ μm^2^. 4--6 H&E-stained sections per animal were analyzed and the data are presented as in (A) (*n* = *6*). **(D)** Cells per islet area. Cell numbers were determined by counting nuclei in 4--6 H&E-stained tissue sections per animal (*n* = *6*). The data are presented as in (A). **(E)** Average numbers of cells per PI. Nuclei were counted in 4--6 H&E-stained serial sections. Data are presented as in (A) (*n* = *6*). **(F)** Cell proliferation in PIs. Consecutive pancreas sections were double stained with the nuclear stain DAPI and an antibody against the nuclear proliferation marker KI67 (see [Supplementary Fig. 3](#appsec1){ref-type="sec"}). Graph shows the proportion of KI67^+^ cells in PIs. Data are presented as in (A) (*n* = *5*). **(G)** Comparison of apoptotic cells in isolated PIs stained with Annexin V-FITC/7AAD-PE apoptosis detection kit from BioLegend (San Diego CA, USA). Analysis was performed using flow cytometry (see [Supplementary Fig. 4](#appsec1){ref-type="sec"}). Numbers of apoptotic cells determined in WT-GDFE or SGLT1^−/−^-GDFE mice are presented relative to numbers obtained for PIs from WT-SC mice. For calculation, numbers obtained for PIs from WT-SC mice were set to 1 for each biological replicate (*n* = *3*). All experiments shown in this figure were performed with male mice. *\*P* \< 0.05, *\*\*P* \< 0.01, ns = not significant ANOVA with posthoc Tukey comparison.Figure 2

3.3. SGLT1 knockout impacts on the β- and α-cell proportion of PIs {#sec3.3}
------------------------------------------------------------------

To gain deeper insights into pancreatic islet cytomorphology, we next performed double immunohistological (IHC) staining\'s on pancreas sections of WT-SC, WT-GDFE, and SGLT^−/-^-GDFE mice with antibodies against insulin and glucagon to investigate the two main endocrine cell types within the islet. In all three groups, two phenotypes of islet cytomorphology could be distinguished: a typical cytomorphology with a core of more than 60% β-cells per PI surrounded by a mantle of less than 20% α-cells per PI, and an atypical cytomorphology characterized by a reduction in the β-cell core (\<60% of PI) and an increased cluster of α-cells (\>20% per PI) ([Figure 3](#fig3){ref-type="fig"}A and B). The number of atypical islets was significantly different between WT-SC, WT-GDFE, and SGLT1^−/−^-GDFE mice ([Figure 3](#fig3){ref-type="fig"}B). We observed 22.4 ± 12.1% atypical islets in WT-SC mice, 40.6 ± 12% in WT-GDFE mice, and 72.2 ± 12.2% in SGLT1^−/−^-GDFE mice. In [Figure 3](#fig3){ref-type="fig"}C and D, the proportion of β- and α-cells per PI without distinguishing between typical and atypical islets is shown. The data indicate similar proportions of β- and α-cells between WT-SC and WT-GDFE mice, whereas SGLT1^−/−^-GDFE mice contained significantly less β- but more α-cells per islet compared to WT-GDFE mice. In contrast, gene expression analysis for insulin and glucagon in isolated PIs, revealed similar mRNA expression levels between WT-GDFE and SGLT^−/-^-GDFE mice compared to WT-SC controls ([Supplementary Figs. 5A and B](#appsec1){ref-type="sec"}).Figure 3**Cytomorphology of pancreatic islets (PIs) from WT-SC, WT-GDFE and SGLT1**^**−/−**^**-GDFE mice.** Individual measurements of β- and α-cell proportions are indicated as means ± SD. **(A)** Representative pictures of PIs with atypical and typical cytomorphology. The PIs were stained with antibodies against insulin for β-cells (INS, green), glucagon for α-cells (GCG, red), and DAPI (blue). Scale bar = 100 μm. *B:* Proportion of PIs showing an atypical cytomorphology (*n* = *6*). Per male animal, 4--6 sections from different stacks were analyzed. **(C,D)** Proportion of β- (C) or α-cells (D) related to total counted cells per islet (*n* = *6*). 4--6 sections of different stacks were analyzed. *\*P* \< 0.05, *\*\*P* \< 0.01, *\*\*\*P* \< 0.001, ns = not significant ANOVA with posthoc Tukey comparison.Figure 3

3.4. Decreased insulin but unchanged glucagon levels are observed after glucose-stimulation of isolated islets from WT-GDFE and SLGT1^−/−^-GDFE mice {#sec3.4}
----------------------------------------------------------------------------------------------------------------------------------------------------

To determine whether the atypical proportion of β- and α-cells in SGLT1^−/−^ islets associates with changes in the secretion of insulin or glucagon, we isolated islets from all three animal groups and measured insulin or glucagon levels after glucose stimulation *in vitro*. We observed a significantly decreased stimulation index for insulin secretion of PIs obtained from WT-GDFE mice compared to WT-SC controls, whereas SGLT1 knockout had no significant effect ([Figure 4](#fig4){ref-type="fig"}A). In contrast, glucagon levels were similar between all three groups independent of low or high glucose concentrations ([Figure 4](#fig4){ref-type="fig"}B and C). In view of the diminished insulin-secretion capacity of WT-GDFE and SGLT1^−/−^-GDFE mice, we analyzed PIs for fat incorporation, as a fat-enriched diet was recently shown to contribute to diminished glucose dependent insulin secretion [@bib30], [@bib31], [@bib32]. Studying triglyceride deposition within PIs were performed by Oil Red O histological stainings. While SGLT1^−/−^-GDFE pancreata displayed a flabby texture in comparison to WT mice on either SC or GDFE-diet indicating possible enrichment in fat, no significant differences in all three groups were detected by the Oil Red O staining ([Supplementary Fig. 6](#appsec1){ref-type="sec"}). Of note and further arguing against an increase in fat, body weight was not only significantly reduced in SGLT1^−/−^-GDFE mice but also in WT-GDFE controls ([Supplementary Fig. 6B](#appsec1){ref-type="sec"}).Figure 4**Glucose-stimulated insulin and glucagon secretion in isolated islets and analysis of Insulin, glucagon, and GLP-1 levels in blood of WT-SC, WT-GDFE, and SGLT1**^**−/−**^**-GDFE mice after glucose administration.** Isolated PIs were cultured in the presence of 3.3 mM [d]{.smallcaps}-glucose followed by incubation for 60 min at 3.3 mM (low glucose) or 16.7 mM [d]{.smallcaps}-glucose (high glucose). Insulin secretion capacity of islets is shown as stimulation index **(A)**. Glucagon levels are shown as absolute values **(B,C)**. Both insulin and glucagon values are normalized to islet DNA. *n* = *4*. Individual measurements are indicated as means ± SD. Concentrations of insulin **(D,E)**,GLP-1 **(F,G)** and glucagon **(H,I)** in systemic blood were analyzed 5 min **(D,F,H)** or 60 min **(E,G,I)** after gavage with phosphate buffered saline without glucose (PBS) or glucose (Glc) in WT-SC, WT-GDFE or SGLT1^−/−^-GDFE animals (*n* = *3 - 6*). The determinations of insulin, GLP-1 and glucagon were performed in duplicates. Islet stimulation and *in vivo* experiments were performed with male mice. Means ± SD and measurements from individual animals are indicated. *\*P* \< *0.05, \*\*P* \< *0.01,* \*\*\**P* \< 0.001, ns = not significant one-way ANOVA with posthoc Tukey test. ^××^P \< 0.01, ^×××^P \< 0.001, ns = not significant Student\'s *t*-test.Figure 4

3.5. SGLT1^−/−^ mice on glucose-deficient, fat-enriched diet show altered blood insulin, glucagon, and GLP-1 levels {#sec3.5}
-------------------------------------------------------------------------------------------------------------------

In order to investigate if the insulin or glucagon secretion capacity of PIs from WT-GDFE mice is compromised *in vivo*, we next performed an oral glucose tolerance test (OGTT). As intestinal GLP-1 secretion is an important regulatory mechanism for insulin secretion [@bib33], which was previously shown to be impaired in SGLT1^−/−^ mice [@bib7], [@bib8] we also analyzed GLP-1 values in this work. Former studies revealed an impaired insulin and GLP-1 secretion in SGLT1^−/−^-GDFE mice 5--15 min after glucose gavage [@bib7], [@bib8]. In these studies, 2--3 months old SGLT1^−/−^ mice on GDFE [@bib7] were analyzed in comparison to either WT mice on SC [@bib7] or GDFE applied for only one week [@bib8]. Our study addresses a prolonged application of the GDFE-diet. We measured insulin and also GLP-1 levels after OGTT in the systemic blood comparing WT-GDFE and SGLT1^−/−^-GDFE mice, both fed the same duration with GDFE-diet ([Figure 4](#fig4){ref-type="fig"}D--G). WT-SC mice served as additional control group. In WT-SC mice 5 min after glucose gavage, blood insulin concentration was increased 3.8-fold ([Figure 4](#fig4){ref-type="fig"}D) and decreased to the fasting level after 60 min ([Figure 4](#fig4){ref-type="fig"}E). This is in contrast to WT-GDFE animals with no significant increase of blood insulin 5 min after glucose gavage but up to 34% increase 60 min after glucose gavage ([Figure 4](#fig4){ref-type="fig"}D and E). In SGLT1^−/−^-GDFE mice, no increase of blood insulin was observed 5 min and 60 min after glucose gavage ([Figure 4](#fig4){ref-type="fig"}D and E) demonstrating no insulin responses at both specific time points when SGLT1 is abrogated. Prompted by these findings, we next investigated if these observations are associated with a deregulation in GLP-1 secretion. Measurements of GLP-1 concentrations 5 min after glucose gavage showed increased blood GLP-1 levels by 80 ± 29 pMol and 58 ± 20 pMol in WT-SC and WT-GDFE mice ([Figure 4](#fig4){ref-type="fig"}F). In contrast, no significant increase of blood GLP-1 was observed in SGLT1^−/−^-GDFE mice ([Figure 4](#fig4){ref-type="fig"}F). 60 min after glucose gavage, blood GLP-1 was not changed in WT-SC mice; however, it was increased by 52 ± 20 pMol in WT-GDFE mice and by 126 ± 62 pMol in SGLT1^−/−^-GDFE mice (P \< 0.05 for difference between WT-GDFE and SGLT1^−/−^-GDFE mice) ([Figure 4](#fig4){ref-type="fig"}G). Analyses of glucagon levels ([Figure 4](#fig4){ref-type="fig"}H and I) revealed a significant increase in blood glucagon for WT-SC and WT-GDFE mice 5 min after glucose administration while SGLT1^−/−^-GDFE mice showed no significantly elevated blood glucagon levels ([Figure 4](#fig4){ref-type="fig"}H). However, increased blood glucagon levels were demonstrated for SGLT1^−/−^-GDFE mice 60 min after glucose administration ([Figure 4](#fig4){ref-type="fig"}I). While glucagon levels for WT-SC mice dropped off after 60 min, WT-GDFE animals displayed marginally elevated blood glucagon levels ([Figure 4](#fig4){ref-type="fig"}I).

4. Discussion {#sec4}
=============

SGLT1 is known to be predominantly expressed in the small intestine playing a leading role in intestinal glucose absorption. Here we demonstrate the downregulation of small intestinal SGLT1 under low glucose conditions. Corresponding to the reduced mRNA expression levels, SGLT1 function also was impaired. A nutrient-dependent regulation of SGLT1 was published recently [@bib2], [@bib27], [@bib34]. In this context, Shirazi-Beechey et al. showed an upregulation of SGLT1 when glucose is high [@bib27]. In summary, these data prove glucose to be an important regulator for small intestinal SGLT1 expression and function while the impact of the dietary fat remains elusive.

Apart from the small intestine, SGLT1 was recently shown to be expressed in various other organs like the pancreas [@bib1], [@bib2], [@bib3], [@bib5], [@bib6], [@bib23], [@bib24]. Pancreatic SGLT1 mRNA was unaltered under diet conditions suggesting different regulatory mechanisms for SGLT1 in diverse tissues. SGLT1 mRNA expression was shown for PIs and the exocrine pancreas; however, at drastically reduced levels compared to the small intestine. The low expression levels could be explained by SGLT1 abundance only in cellular subsets of both pancreatic regions. While SGLT1 expression is described for all islet cell types except of β-cells, exocrine-specific expression was shown only for duct cells [@bib3], [@bib6], [@bib23].

In light of pancreatic SGLT1 expression and due to a lack of knowledge about its function, we investigated if loss of SGLT1 impacts PIs. Our data provided evidence for an aberrant pancreatic islet morphology including enlarged sizes associated with elevated cell numbers but unchanged cellular densities. Further, apoptotic cell numbers were reduced explaining the increase in islet cell numbers and therefore size. In addition, the majority of SGLT1^−/−^ islets displayed an atypical cytomorphology characterized by a decrease of the β- and increase of the α-cell proportion. Prolonged feeding of mice with GDFE also resulted in atypical islet cytomorphology. However, the proportion of α- and β-cells was not significantly altered in WT-GDFE mice, albeit marginal differences to WT-SC controls were observed. As SGLT1 expression was only reduced, but not completely abolished, in GDFE fed wild type mice, the remaining SGLT1 expression may account for these differences in effect strength between WT-GDFE and SGLT1^−/−^ islets. In summary, our data hypothesize a role for SGLT1 maintaining typical islet (cyto)morphology including cellular composition of the islet. Mechanistically, these observations could rely on an impairment in glucose transport and/or sensing due to loss of SGLT1. Glucose is known to be of high importance for PIs, regulating β-cell survival and proliferation in an age- and dose-dependent manner [@bib35], [@bib36]. Diminished survival and proliferation rates were demonstrated with decreasing glucose concentrations [@bib35]. Further, elevated glucose levels are associated with increased islet cell apoptosis [@bib37], [@bib38]. Loss of SGLT1 associated with an underrepresentation of postprandial blood glucose could therefore explain the impaired cellular proliferation and reduction in apoptotic cells. Given that SGLT1 expression was shown for diverse islet-specific cell types [@bib3], [@bib6], loss of SGLT1 function could further result in aberrant glucose transport and/or sensing within the pancreatic islet. In this context, we hypothesize that the lack of SGLT1 function possibly promotes a rescue mechanism within the murine islet to cope with the unavailability of glucose by increasing the proportion of glucagon-secreting α-cells thereby driving gluconeogenesis. To what extent intestinal or pancreatic SGLT1 function contribute needs to be addressed in future studies.

To date, a detailed understanding for the increase in α-cells is missing. As cellular plasticity was shown for pancreatic islet cells [@bib39], one possible explanation would be the transdifferentiation of other islet cell types into α-cells but an exocrine origin also would be conceivable. SGLT1 expression was recently demonstrated within intralobular duct cells of the pancreas [@bib6], [@bib23] but functional aspects remain unknown. Given that pancreatic duct cells represent progenitors for all endocrine cell types during development [@bib40], [@bib41], [@bib42], it would be of great interest to know if loss of SGLT1 function is associated with a change in interstitial glucose concentration and if this affects islet morphology and/or cellular alterations already at early developmental stages. Future long-term studies are urgently needed to investigate if SGLT1 ablation is indeed associated with disturbed glucose transport and/or sensing possibly contributing to the onset, progression and/or manifestation of the altered (cyto)morphology observed in SGLT1^−/−^ islets. In addition, using a conditional knockout mouse model specific for pancreatic islet cell types will highlight if intestinal or pancreatic SGLT1 accounts for the impact on PIs.

In addition to structural aspects, our data provided evidence for aberrant insulin responses of WT and SGLT1^−/−^ mice on GDFE diet. Mechanistically, loss of SGLT1 and feeding GDFE diet results in lower blood glucose levels compared to wild type mice on standard chow and therefore a limitation of the main regulator for insulin secretion from pancreatic β-cells. This proposes a dysfunction of the intestine regarding its glucose absorbance capacity as an underlying mechanism for the attenuated insulin responses. However, glucose stimulation of isolated islets from WT-GDFE or SGLT1^−/−^-GDFE mice demonstrated lower stimulation indexes compared to WT-SC mice, a finding that indicates an impaired functionality of the β-cell itself. A detailed knowledge about cellular or molecular reasons as well as physiological causes remains unknown and needs to be addressed in detail in future studies.

In the past, a direct relation between fat-enriched diets and impaired insulin responses was demonstrated [@bib30], [@bib31], [@bib32], [@bib43]. As dietary fat is known to change lipid composition in islet cell membranes, therefore hindering glucose transport and/or glucose sensing [@bib31], the fat component of the GDFE diet could explain our findings regarding the impaired or absent insulin responses. However, we could not detect the incorporation of fat within PIs or anywhere in the pancreas (see [Fig. S6C](#appsec1){ref-type="sec"}). In conclusion, these data point to another mechanism that contributes to the decreased insulin secretion capacity of WT or SGLT1^−/−^ mice on GDFE diet.

Along with the SGLT1-mediated glucose absorption, the secretion of GLP-1 from enteroendocrine L-cells is regulated within the intestine which further stimulates insulin-secretion from pancreatic β-cells in addition to glucose [@bib9], [@bib10], [@bib11]. In line with recent publications, we demonstrate no GLP-1 response in SGLT1^−/−^-GDFE mice 5 min after OGTT contributing to the missing rise in blood insulin in these animals at this time point. Furthermore, this finding underlines the importance of SGLT1 in the regulation of acute GLP-1 secretion [@bib7], [@bib24], [@bib44]. In contrast to SGLT1^−/−^ mice, WT-GDFE animals showed an acute GLP-1 secretion but also no insulin response. Despite the secretion of GLP-1, blood glucose levels that are too low or possibly dysfunctional β-cells in these mice most likely account for this observation.

Both GDFE-fed animal groups displayed a sustained release of GLP-1 measured 60 min after OGTT. Similar findings were recently observed for SGLT1^−/−^ mice demonstrating the delivery of glucose to the more distal gut and thereby initiating the sustained release of GLP-1 when SGLT1 is absent [@bib13], [@bib14], [@bib45]. The reduced expression of SGLT1 in WT-GDFE mice possibly explains the sustained release of GLP-1 in these mice, similar to what is observed in SGLT1^−/−^ animals. The sustained release of GLP-1 also might explain recently published results that demonstrate a weak insulin response in SGLT1^−/−^ mice 10 - 15 min after OGTT, a time point that was not analyzed in our study [@bib7], [@bib8]. Together with our findings, these data suggest a delayed insulin response mainly triggered by sustained GLP-1 release in the absence of SGLT1. As the increase in blood insulin shown by recent studies was only marginal, an impairment or dysfunction of β-cells for insulin secretion is further supported. This dysfunction possibly arises during development and manifests throughout aging due to the low levels of blood glucose.

As glucagon secreted from α-cells is known to counteract rising insulin levels in the blood, our data further indicate a dominant role for glucagon in the context of the impaired rise in blood insulin levels observed for WT-GDFE or SGLT1^−/−^-GDFE mice. In both animal groups, increased glucagon levels could be detected compared to PBS controls 5 and 60 min after OGTT. Stimulation of glucagon release from α-cells in the absence of insulin can be triggered by hypoglycemia [@bib46]. Possible mechanistic explanations include the control of glucagon secretion via effector molecules like Zn^2+^ [@bib47], γ-aminobutyric acid [@bib48] or somatostatin [@bib49]. Further, neuronal regulated glucose sensing [@bib50], [@bib51] or the hyperpolarization of the α-cell due to low blood glucose could play a role [@bib52]. To what extent which of these possibilities contribute to our findings remains elusive.

5. Conclusion {#sec5}
=============

In summary, loss or impairment of SGLT1 resulted in abnormal pancreatic islet (cyto)morphology and disturbed islet function in the context of insulin or glucagon secretion from β- or α-cells, respectively. As a result, our findings propose a new, additional role for SGLT1 in maintaining proper islet structure and function.

In view of the recently published positive impact of SGLT1 inhibition on postprandial blood glucose levels under healthy or diabetic conditions [@bib7], [@bib8], [@bib14], [@bib15], [@bib16], our data further signify the urgent need of long-term studies to investigate possible tissue-specific side effects when SGLT1 function is lost or impaired.
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